Lantheus Holdings (NASDAQ: LNTH) Downgraded to Hold Amidst Curium Acquisition

• Cowen & Co. downgraded Lantheus Holdings (NASDAQ: LNTH) to "Hold" following its acquisition agreement with Curium.
• The $6.7 billion acquisition offers shareholders $102.50 per share in cash, with potential additional $12.00 per share via Contingent Value Rights (CVRs).
• A law firm is investigating the deal's fairness, particularly regarding the contingent nature of CVR payments.

Lantheus Holdings (NASDAQ: LNTH) is a leading radiopharmaceutical company specializing in diagnostic imaging agents and products. These innovative products assist medical professionals in diagnosing critical conditions in areas like cardiology and oncology. On August 3, 2026, the reputable analyst firm Cowen & Co. adjusted its stock rating for Lantheus from a "Buy" to a "Hold" when the stock's price was $102.18.

This significant rating change coincides with Lantheus's agreement to be acquired by Curium, a prominent global radiopharmaceutical competitor. As reported by the Wall Street Journal, this strategic acquisition deal carries an initial value of $6.7 billion. The merger aims to integrate Curium's extensive global manufacturing capabilities with Lantheus's robust U.S. diagnostics business, ultimately serving patients across more than 70 countries, according to GlobeNewsWire.

Cowen & Co.'s "Hold" investment rating likely stems from the fixed acquisition price. Shareholders of Lantheus are slated to receive $102.50 in cash for each share. This cash offer is notably close to the $102.18 stock price at the time of the downgrade, suggesting limited potential for further stock price appreciation for investors.

The acquisition agreement also incorporates a potential additional payment mechanism through Contingent Value Rights (CVRs). A CVR represents a right granted to shareholders to receive future cash payments contingent upon the company achieving specific performance goals. For Lantheus shareholders, these CVRs could potentially add up to an extra $12.00 per share to their total payout.

Despite the prospect of a higher overall payout, the law firm Ademi LLP has initiated an investigation into the acquisition deal. The firm is scrutinizing whether the transaction price is equitable for public shareholders. It specifically highlights that the CVR payments are conditional on achieving specific sales targets through 2030 and are therefore not guaranteed, raising concerns about investor fairness.